A reduced dose of elective radiation is safe and does not compromise treatment efficacy in patients with head and neck ...

Cancer is a debilitating illness that remains a persistent threat to humanity and is one of the leading causes of death ...

External-beam radiation therapy for head and neck cancers delivers radiation from a machine outside the body to destroy a cancer’s DNA, denying it instructions to grow and multiply. A radiation ...

More Americans are beating cancer than ever, yet many still grapple with treatment's long shadow—especially on their mental ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

The primary endpoint was the mean normalcy of diet score on the clinician-rated Performance Status Scale for Head and Neck at 1 year. The mean score was 91.6 in the dose-reduction arm and 92.6 in the ...

A new Northwestern Medicine study found most head-and-neck cancer survivors who underwent radiation don’t know about ...

Sun Nuclear, a Mirion Medical company, today announced the acquisition of Oncospace, a company providing cloud-based, AI-powered solutions for the radiation oncology community. This strategic move ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...